GlassScriptPhysician profile
Ayham Al Ashkar
NPI 1417084799
$2,034.25
in general payments reported to CMS, 2019-2025
32 companies · $63.09 in 2025
The $63.09 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $49.22 · 2021: $94.96 · 2022: $813 · 2023: $612 · 2024: $15.52 · 2025: $63.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.59 |
| Education | $170.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $230.34 | 2021-2025 | Fotivda |
| Pfizer INC. | $194.90 | 2019-2025 | |
| Amgen INC. | $179.28 | 2020-2022 | |
| Genentech USA, INC. | $162.72 | 2022-2023 | Venclexta |
| Janssen Biotech, INC. | $135.95 | 2019 | |
| Glaxosmithkline, LLC. | $122.03 | 2022 | |
| Merck Sharp & Dohme LLC | $98.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $91.09 | 2021-2022 | |
| Mirati Therapeutics, INC. | $85.23 | 2023-2024 | Krazati |
| Seagen INC. | $79.52 | 2020-2022 | |
| Gilead Sciences, INC. | $73.25 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $61.44 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $54.61 | 2023 | Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $51.05 | 2019-2023 | |
| Celgene Corporation | $47.37 | 2022-2023 | Reblozyl |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $38.48 | 2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $38.46 | 2022-2023 | Onivyde, Somatuline Depot |
| Pharmacyclics LLC, An Abbvie Company | $37.88 | 2019-2023 | Imbruvica |
| Tesaro, INC. | $28.73 | 2019 | |
| Kite Pharma, INC. | $27.20 | 2021-2022 | |
| Astellas Pharma US INC | $26.86 | 2022-2023 | Xospata |
| Taiho Oncology, INC. | $25.71 | 2023 | |
| Rigel Pharmaceuticals, INC. | $18.62 | 2023 | Tavalisse, Rezlidhia |
| Morphosys, US INC. | $18.59 | 2022 | |
| Stemline Therapeutics INC. | $17.00 | 2023 | Orserdu |
| Dendreon Pharmaceuticals LLC | $15.96 | 2019 | |
| Beigene USA, INC. | $15.92 | 2023 | Brukinsa |
| Lilly USA, LLC | $15.78 | 2019 | |
| G1 Therapeutics, INC. | $12.74 | 2022 | |
| Fortovia Therapeutics, INC. | $11.64 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Penumbra, INC. | $6.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayham Ashkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.